Ceapro Inc. Presents Encouraging Results from Research Collaboration Study with McMaster University Evaluating PGX-Processed Yeast Beta Glucan for Interstitial Lung Diseases

EDMONTON, Alberta, May 23, 2023 (GLOBE NEWSWIRE) --  Ceapro Inc.  (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced encouraging results from it’s completed pre-clinical CHRP study conducted with McMaster University evaluating PGX-processed yeast beta glucan (PGX-YBG) as a potential therapeutic option for individuals suffering from interstitial lung diseases (ILD).